Polar Capital Holdings PLC Cerevel Therapeutics Holdings, Inc. Transaction History

Polar Capital Holdings PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$20.26 - $31.91 $18.2 Million - $28.7 Million	-900,000 Reduced 98.82%	10,762 $234,000
Q2 2023 Dec 13, 2023	BUY	$23.9 - $35.38 $3.41 Million - $5.04 Million	142,486 Added 18.55%	910,762 $29 Million
Q2 2023 Aug 14, 2023	BUY	$23.9 - $35.38 $3.41 Million - $5.04 Million	142,486 Added 18.55%	910,762 $29 Million
Q1 2023 Dec 13, 2023	BUY	$22.82 - $35.32 $17.3 Million - $26.8 Million	757,514 Added 7038.78%	768,276 $18.7 Million
Q1 2023 May 15, 2023	BUY	$22.82 - $35.32 $6.78 Million - $10.5 Million	296,961 Added 63.01%	768,276 $18.7 Million
Q4 2022 Feb 14, 2023	SELL	$25.35 - $31.96 $1.19 Million - $1.5 Million	-46,961 Reduced 9.06%	471,315 $14.9 Million
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $466,038 - $756,991	18,276 Added 3.66%	518,276 $14.6 Million
Q2 2022 Aug 15, 2022	SELL	$20.62 - $37.15 $5.16 Million - $9.29 Million	-250,000 Reduced 33.33%	500,000 $13.2 Million
Q3 2021 Nov 15, 2021	BUY	$21.26 - $38.85 $14.9 Million - $27.2 Million	700,000 Added 1400.0%	750,000 $22.1 Million
Q2 2021 Aug 16, 2021	BUY	$12.56 - $29.69 $628,000 - $1.48 Million	50,000 New	50,000 $1.28 Million

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Polar Capital Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Polar Capital Holdings PLC with notifications on news.